Overview

Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of clofarabine, cytarabine, and idarubicin can help to control Acute Myeloid Leukemia (AML) in patients who are between the ages of 18 and 60 years old. The safety of this study drug combination will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Genzyme, a Sanofi Company
Treatments:
Clofarabine
Cytarabine
Idarubicin